A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors

Leo Mascarenhas, Marcio Malogolowkin, Saro H. Armenian, Richard Sposto, Rajkumar Venkatramani

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: The combination of a platinum agent and anthracycline has shown activity in pediatric solid tumors. This trial evaluated the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin combined with doxorubicin in pediatric patients with recurrent solid tumors. Methods: Oxaliplatin was administered on day 1 and Doxorubicin on days 1-3 of each 21 day course. The study utilized a standard 3+3 dose escalation design. Three dose levels were evaluated: (1) oxaliplatin 105mg/m2 and doxorubicin 20mg/m2; (2) oxaliplatin 130mg/m2 and doxorubicin 20mg/m2; and (3) oxaliplatin 130mg/m2 and doxorubicin 25mg/m2. Dexrazoxane was administered at 10 times the doxorubicin dose prior to doxorubicin infusion. Results: Seventeen patients were enrolled. Dose level 1 was the determined MTD. Grade 2 cardiac DLT was seen in one of six patients on dose level 1, grade 4 thrombocytopenia in two of five patients on dose level 2, and one each of grade 2 cardiac and grade 4 thrombocytopenia in five patients on dose level 3. Cardiac DLT was only noted in patients with prior exposure to both anthracycline and chest radiation. No grade 3 or 4 neurotoxicity or mucositis was seen. Objective responses were noted in two patients with neuroblastoma and one each of mixed germ cell tumor, thymic neuroendocrine carcinoma, and nasopharyngeal carcinoma. Conclusions: Oxaliplatin 105mg/m2 on day 1 combined with doxorubicin 20mg/m2 days 1-3 was the MTD. This combination shows sufficient activity to justify further studies in select pediatric tumors.

Original languageEnglish (US)
Pages (from-to)1103-1107
Number of pages5
JournalPediatric Blood and Cancer
Volume60
Issue number7
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

oxaliplatin
Doxorubicin
Pediatrics
Maximum Tolerated Dose
Neoplasms
Anthracyclines
Dexrazoxane
Neuroendocrine Carcinoma
Mucositis
Thymoma
Germ Cell and Embryonal Neoplasms
Platinum
Neuroblastoma

Keywords

  • Children
  • Doxorubicin
  • Oxaliplatin
  • Phase I
  • Recurrent
  • Refractory
  • Relapsed
  • Solid tumors

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. / Mascarenhas, Leo; Malogolowkin, Marcio; Armenian, Saro H.; Sposto, Richard; Venkatramani, Rajkumar.

In: Pediatric Blood and Cancer, Vol. 60, No. 7, 01.07.2013, p. 1103-1107.

Research output: Contribution to journalArticle

Mascarenhas, Leo ; Malogolowkin, Marcio ; Armenian, Saro H. ; Sposto, Richard ; Venkatramani, Rajkumar. / A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 7. pp. 1103-1107.
@article{6d2e1cd826b145eca5db22e0f46e3784,
title = "A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors",
abstract = "Background: The combination of a platinum agent and anthracycline has shown activity in pediatric solid tumors. This trial evaluated the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin combined with doxorubicin in pediatric patients with recurrent solid tumors. Methods: Oxaliplatin was administered on day 1 and Doxorubicin on days 1-3 of each 21 day course. The study utilized a standard 3+3 dose escalation design. Three dose levels were evaluated: (1) oxaliplatin 105mg/m2 and doxorubicin 20mg/m2; (2) oxaliplatin 130mg/m2 and doxorubicin 20mg/m2; and (3) oxaliplatin 130mg/m2 and doxorubicin 25mg/m2. Dexrazoxane was administered at 10 times the doxorubicin dose prior to doxorubicin infusion. Results: Seventeen patients were enrolled. Dose level 1 was the determined MTD. Grade 2 cardiac DLT was seen in one of six patients on dose level 1, grade 4 thrombocytopenia in two of five patients on dose level 2, and one each of grade 2 cardiac and grade 4 thrombocytopenia in five patients on dose level 3. Cardiac DLT was only noted in patients with prior exposure to both anthracycline and chest radiation. No grade 3 or 4 neurotoxicity or mucositis was seen. Objective responses were noted in two patients with neuroblastoma and one each of mixed germ cell tumor, thymic neuroendocrine carcinoma, and nasopharyngeal carcinoma. Conclusions: Oxaliplatin 105mg/m2 on day 1 combined with doxorubicin 20mg/m2 days 1-3 was the MTD. This combination shows sufficient activity to justify further studies in select pediatric tumors.",
keywords = "Children, Doxorubicin, Oxaliplatin, Phase I, Recurrent, Refractory, Relapsed, Solid tumors",
author = "Leo Mascarenhas and Marcio Malogolowkin and Armenian, {Saro H.} and Richard Sposto and Rajkumar Venkatramani",
year = "2013",
month = "7",
day = "1",
doi = "10.1002/pbc.24471",
language = "English (US)",
volume = "60",
pages = "1103--1107",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors

AU - Mascarenhas, Leo

AU - Malogolowkin, Marcio

AU - Armenian, Saro H.

AU - Sposto, Richard

AU - Venkatramani, Rajkumar

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Background: The combination of a platinum agent and anthracycline has shown activity in pediatric solid tumors. This trial evaluated the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin combined with doxorubicin in pediatric patients with recurrent solid tumors. Methods: Oxaliplatin was administered on day 1 and Doxorubicin on days 1-3 of each 21 day course. The study utilized a standard 3+3 dose escalation design. Three dose levels were evaluated: (1) oxaliplatin 105mg/m2 and doxorubicin 20mg/m2; (2) oxaliplatin 130mg/m2 and doxorubicin 20mg/m2; and (3) oxaliplatin 130mg/m2 and doxorubicin 25mg/m2. Dexrazoxane was administered at 10 times the doxorubicin dose prior to doxorubicin infusion. Results: Seventeen patients were enrolled. Dose level 1 was the determined MTD. Grade 2 cardiac DLT was seen in one of six patients on dose level 1, grade 4 thrombocytopenia in two of five patients on dose level 2, and one each of grade 2 cardiac and grade 4 thrombocytopenia in five patients on dose level 3. Cardiac DLT was only noted in patients with prior exposure to both anthracycline and chest radiation. No grade 3 or 4 neurotoxicity or mucositis was seen. Objective responses were noted in two patients with neuroblastoma and one each of mixed germ cell tumor, thymic neuroendocrine carcinoma, and nasopharyngeal carcinoma. Conclusions: Oxaliplatin 105mg/m2 on day 1 combined with doxorubicin 20mg/m2 days 1-3 was the MTD. This combination shows sufficient activity to justify further studies in select pediatric tumors.

AB - Background: The combination of a platinum agent and anthracycline has shown activity in pediatric solid tumors. This trial evaluated the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin combined with doxorubicin in pediatric patients with recurrent solid tumors. Methods: Oxaliplatin was administered on day 1 and Doxorubicin on days 1-3 of each 21 day course. The study utilized a standard 3+3 dose escalation design. Three dose levels were evaluated: (1) oxaliplatin 105mg/m2 and doxorubicin 20mg/m2; (2) oxaliplatin 130mg/m2 and doxorubicin 20mg/m2; and (3) oxaliplatin 130mg/m2 and doxorubicin 25mg/m2. Dexrazoxane was administered at 10 times the doxorubicin dose prior to doxorubicin infusion. Results: Seventeen patients were enrolled. Dose level 1 was the determined MTD. Grade 2 cardiac DLT was seen in one of six patients on dose level 1, grade 4 thrombocytopenia in two of five patients on dose level 2, and one each of grade 2 cardiac and grade 4 thrombocytopenia in five patients on dose level 3. Cardiac DLT was only noted in patients with prior exposure to both anthracycline and chest radiation. No grade 3 or 4 neurotoxicity or mucositis was seen. Objective responses were noted in two patients with neuroblastoma and one each of mixed germ cell tumor, thymic neuroendocrine carcinoma, and nasopharyngeal carcinoma. Conclusions: Oxaliplatin 105mg/m2 on day 1 combined with doxorubicin 20mg/m2 days 1-3 was the MTD. This combination shows sufficient activity to justify further studies in select pediatric tumors.

KW - Children

KW - Doxorubicin

KW - Oxaliplatin

KW - Phase I

KW - Recurrent

KW - Refractory

KW - Relapsed

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=84878217873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878217873&partnerID=8YFLogxK

U2 - 10.1002/pbc.24471

DO - 10.1002/pbc.24471

M3 - Article

C2 - 23335436

AN - SCOPUS:84878217873

VL - 60

SP - 1103

EP - 1107

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -